bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day. The surge came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the stock since Feb 5, as it is now up nearly 40%.
In the last 30 days, the company did not see any estimate revision and the Zacks Consensus Estimate hasn’t been in a trend either. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
bluebird bio currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the medical sector include Emergent BioSolutions, Inc. (EBS), Gilead Sciences Inc. (GILD) and Halozyme Therapeutics, Inc. (HALO). While Emergent and Gilead sport a Zacks Rank #1 (Strong Buy), Halozyme carries a Zacks Rank #2 (Buy) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment